請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37328完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 賴裕和(Yeur-Hur Lai) | |
| dc.contributor.author | Ting-Fang Tsai | en |
| dc.contributor.author | 蔡婷芳 | zh_TW |
| dc.date.accessioned | 2021-06-13T15:24:34Z | - |
| dc.date.available | 2009-08-13 | |
| dc.date.copyright | 2008-08-13 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-22 | |
| dc.identifier.citation | 中文部份
王文娟（2004）．頭頸癌患者症狀嚴重度、情緒狀態與睡眠品質之探討．未發表碩士論文，台北，台北護理學院護理學研究所。 行政院衛生署國民健康局（2003）•中華民國九十二年癌症登記年度報告•取自9月15日，2007，http://crs.cph.ntu.edu.tw/crs_c/annual.html 行政院衛生署（2005，12月30日）．94年衛生統計系列與因統計．上冊．衛生署衛生統計資訊網，取自5月5日，2007， http://www.doh.gov.tw/statistic/data/衛生統計叢書2/94/上冊/目錄.htm。 何明霖（2005）．肺癌流行病學．肺癌關懷團體網，取自5月29日，2007，http://www2.cch.org.tw/lungcancer/CR_PR_SD.htm 李明陽、王緯書、陳博明（2004）•化學治療引起周邊神經病變之預防及治療•臨床醫學，54（6），407-412。 李芸湘、蔡芸芳、賴裕和、高瑞和（2002）•肺癌病患在化學治療期間疲憊程度及其相關因素•台灣醫學，6（6），797-804。 高翡勵（2003）．接受胃切除胃癌病人的症狀嚴重度、不確定感與希望狀態之探討．未發表碩士論文，台北，臺北醫學大學護理學研究所。 徐翠霞（2001）．肺癌病患之疼痛程度與不確定感和希望狀態的相關性．未發表碩士論文，台北，臺北醫學大學護理學研究所。 張青蕙（2003）．住院癌症病患疲憊問題及其相關因素之探討．未發表碩士論文，台北，臺北醫學大學護理學研究所。 張雪會（2006）．老人視力障礙與視覺功能生活品質之流行病學研究．未發表碩士論文，台北，輔仁大學公共衛生學研究所。 黃怡菁、唐婉如、史麗珠、余志騰（2005）•肺癌病患化療期間之疲憊軌跡•腫瘤護理雜誌，5（2），15-27。 陸坤泰、張登斌（2001）．台灣的肺癌．台灣醫學會，取自5月30日，2008，http://fma.mc.ntu.edu.tw/oldweb/data/％AA％CD％C0％F9.html 姜紹青（2006）•抗癌化學藥物治療原則簡介•腫瘤護理雜誌，6（1），1-8。 姚如玲（2005）．影響肺癌病人疲憊、憂鬱與睡眠品質之相關因素探討．未發表碩士論文，台北，臺北醫學大學護理學研究所。 劉會平（2004）•肺癌的診斷及治療•腫瘤護理雜誌，4（2），25-34。 葉坤輝、鄭安理（1998）•癌症化學治療之適應症•台灣醫學，2（3），305-311。 楊志新、鄭安理（1998）•癌症化學治療之新藥•台灣醫學，2（3），312-315。 陳珮瑛（2004）．以縱貫式研究探討急性白血病患化學治療的經驗．未發表碩士論文，台北，臺北醫學大學護理學研究所。 陳佩英、史麗珠、王正旭、賴裕和、張獻崑、陳美伶（1999）．疼痛對癌症病患焦慮與憂鬱之影響．台灣醫學，3（4），373-382。 賴裕和（ 1998 ）•門診接受化學治療病人之症狀困擾及居家護理需求探討•護理研究，6（4），279-289。 謝松蒼（1998）•周邊神經病變簡介•當代醫學，25（11），877-883。 英文部分 Argyriou, A. A., Polychronopoulos, P., Koutras, A., Iconomou, G.., Gourzis, P., Assimakopoulos, K., Kalofonos, H. P., Chroni, E.（2006）. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. Supportive Care in Cancer, 14（3）. 223-229. Akechi, T., Okuyama, T., Akizuki, N., Shimizu, K., Inagaki, M., Fujimori, M. Shima, Y., Furukawa, T. A., & Uchitomi, Y.（2006）. Associated and predictive factors of sleep disturbance in advanced cancer patients. Psycho-Oncology, 16（10）. 888-894. Armstrong, T., Almadrones, L., & Gillbert, M. R.（2005）. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32（2）. 305-311. Almadrones, L., McGuire, D. B., Walczak, J. R., Florio, C. M., & Tian, C.（2004）. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncology Nursing Forum, 31（3）. 615-623. BPharm, M. G., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K. S., & Stacey, B.（2005）. Pain severity in diabetic peripheral neuropathy is associated with patient function, symptom levels of anxiety and depression, and sleep. Journal of Pain and Symptom Management, 30（4）. 374-385. Beck, S. L., Dudley, W. N., & Barsevick, A.（2005）. Pain, sleep disturbance, and fatigue in patients with cancer: using a mediation model to test a symptom cluster. Oncology Nursing Forum. Online, 32（3）. 542. Cooley, M. E., Short, T. H., & Moriarty, H. J.（2003）. Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer. Psycho-Oncology, 16（10）. 888-894. De Petris, L., Crino, L., Scagliotti, G. V., Gridelli, C., Galetta, D., Metro, G., Novello, S., Maione, P., Colucci, G., & de Marinis, F.（2006）. Treatment of advanced non-small cell lung cancer. Annals of Oncology, 17（Suppl 2）. ii36–ii41. Daniel Soper's.（2004）. HIERARCHICAL MULTIPLE REGRESSION A-priori Sample Size Calculator, http://danielsoper.com/statcalc/calc16.aspx（accessed 2007 August 12） Davidson, J. R., MacLeana, A. W., Brundageb, M. D., & Schulze, K.（2002）. Sleep disturbance in cancer patients. Social Science & Medicine, 54（9）. 1309-1321. Du Bois, A., Schlaich, M., Luck, H. J., Mollenkopf, A., Wechsel, U., Rauchholz, M. Bauknecht, T., & Meerpohl, H. G..（1999）. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Supportive Care in Cancer, 7（5）. 354-61. Earl, H. M., Connolly, S., Latoufis, C., Eagle, K., Ash, C. M,, Fowler, C., & Souhami, R. L.（1998）. Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas. Sarcoma, 2（2）. 97-105. Fortner, B. V., Stepanski, E. J., Wang, S. C., Kasprowicz, S., & Durrence, H. H.（2002）. Sleep and quality of life in breast cancer patients. Journal of Pain & Symptom Management, 24（5）. 471-80. Gatzemeier, U., Pawel, J., Gottfried, M., Velde, Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., Bogaerts, J., & Gallant, G.（2000）. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 18（19）. 3390-3399. Ger, L. P., Ho, S. T., Sun, W. Z., & Wang, M. S. Cleeland, C. S.（1999）. Validation of the brief pain inventory in a Taiwanese population. Journal of Pain & Symptom Management, 18（5）. 316-322. Galer, B. S., & Jensen, M. P.（1997）. Development and of a pain measure preliminary validation specific to neuropathic pain: The Neuropathic Pain Scale. Neurology, 48（2）. 332-338. Huang, H. Q., Brady, M. F., Cella, D., & Fleming, G.（2007）. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. International Journal of Gynecological Cancer, 17（2）. 387-393. Hays, R. D., Martin, S. A., Sesti, A. M., & Spritzer, K. L.（2005）. Psychometric properties of the Medical Outcomes Study sleep measure. Sleep Medicine, 6（1）. 41-44. Huang, C. C., Liu, M. T., Pi, C. P., Chang, T. H., Wang, A. Y., & Huang, C. Y.（2005）. Treatment results of chemotherapy and radiotherapy in limited-stage small cell lung cancer. Therapeutic Radiology and Oncology, 12（1）. 27-37. Hays, R.D., & Stewart, A.L.（1992a）. Sleep measures. In A.L. Stewart & J.E. Eare（eds.）, Measuring functioning and well-being: The Medical Outcomes Study approach（pp.235-259）, Durham, NC: Duke University Press. Jensen, M. P., Friedman, M., Bonzo, D., & Richards, P.（2006）. The Validity of the Neuropathic Pain Scale for Assessing Diabetic Neuropathic Pain in a Clinical Trial. Clinical Journal of Pain, 22（1）. 97-103. Krarup-Hansen, A., Helweg-Larsen, S., Schmalbruch, H., Rorth, M., & Krarup, C.（2007）. Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies. Brain, 130. 1076-1088. Kirchmair, R., et al.,（2005）. Antiangiogenesis Mediates Cisplatin-Induced Peripheral Neuropathy Attenuation or Reversal by Local Vascular Endothelial Growth Factor Gene Therapy Without Augmenting Tumor Growth. Circulation, 111. 2662-2670. Kuo, H. H., Chiu, M. J., Liao, W. C., & Hwang, S. L.（2006）. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. Journal of the Formosan Medical Association, 105（1）. 64-69. Kvale, E. A., & Shuster, J. L.（2006）. Sleep disturbance in supportive care of cancer: a review. Journal of Palliative Medicine, 9（2）. 437-50. Mystakidoua, K., Parpaa, E., Tsilikaa, E., Pathiakia, M., Patirakib, E., Galanosa, A., & Vlahos, Lambros.（2007a）. Sleep quality in advanced cancer patients. Journal of Psychosomatic Research, 62（5）. 527– 533. Mystakidou, K., Parpa, E., Tsilika, E., Pathiaki, M., Gennatas, K., Smyrniotis, V., & Vassiliou, I.（2007b）. The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep, 30（6）. 737-42. Marlon, H., Evans, B., Adrienne, H., & Michael, T.（2002）. Neuropathic pain.:Associated physiology and pharmacology. The U.S. Pharmacist Continuing Education Program is approved in all states where continuing education is mandatory. ACPE Program No. 430-000-02-192-H01. McCorkle, R., & Young, K.（1978）. Development of a symptom distress scale. Cancer Nursing, 1（10）,373-378. National Cancer Institute. U.S.（April, 30 1999）. COMMON TOXICITY CRITERIA（CTC）FINAL CTC Version 2.0, https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/Common_Toxicity_Criteria_CTC_v2.htm（accessed 2007 August 9）. Ocean, A. J., & Vahdat, L. T.（2004）. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12（9）. 619-625. Palesh, O. G., Collie, K., Batiuchok, D., Tilston, J., Koopman, C., Perlis, M. L., Butler, L. D., Carlson, R., & Spiegel, D.（2007）. A longitudinal study of depression, pain, ans stress as predictors of sleep disturbance among women with metastatic breast cancer. Biological psychology, 75（1）. 37-44. Polomano, R. C., & Farrar, J. T.（2006）. Pain and neuropathy in cancer survivors. American Journal of Nursing, 106（3）. 39-47. Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., et al.,（2005）. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41（8）. 1135-9. Quasthoff, S., & Hartung, H. P.（2002）. Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249（1）. 9-17. Richiemer, S., & Macres, S.（2000）. Understanding Neuropathic Pain. http://www.spineuniverse.com/treatment/pain/ag_060500richeiner_neuropain.html（accessed 2007 August 21）. Rejas, J., Ribera, M. V., Ruiz, M., & Masrramon, X.（2007）. Psychometric properties of the MOS（Medical Outcomes Study）Sleep Scale in patients with neuropathic pain. European Journal of Pain, 11（3）. 329–340. Rigas, J. R.（2004）. Taxane-platinum combinations in advanced non-small cell lung cancer: A review. Oncologist, 9.（suppl 2）. 16-23. Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., Ungaro, P., Norton, L., Winer, E., & Hudis, C.（2008）. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of Clinical Oncology, 26（10）. 1642-1649. Seidman, A. D., Hudis, C. A., Albanell, J., Tong, W., Tepler, I., Currie, V., Moynahan, M. E., Theodoulou, M., Gollub, M., Baselga, J., & Norton, L.（1998）. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Journal of Clinical Oncology, 16（10）. 3353-3361. Serlin, R. C., Mendoza, T. R., Nakamura, Y., Edwards, K. R., & Cleeland, C. S.（1995）. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain, 61. 277-284. Visovsky, C. & Daly, B. J.（2004）. Clinical evaluation and patterns of chemotherapy-indeced peripheral neuropathy. Journal of The American Academy of Nursing Practitioners, 16（8）. 353-359. Verstappen, C. C., Heimans, J. J., Hoekman, K., & Postma, T. J.（2003）. Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63（15）. 1549-1563. Vosvick, M., Gore-Felton, C., Ashton, E., Koopman, C., Fluery, T., Israelski, D., & Spiegel, D.（2004）. Sleep disturbances among HIV-positive adults: the role of pain, stress, and social support. Journal of Psychosomatic Research, 57（5）. 459-63. Wickham, R.（2007）. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11（3）. 361-376. Wampler, M. A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, K. S.（2006）. The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. The Journal of Supportive Oncology, 4（8）. 9-16. Wampler, M. A., Hamolsky, D., Hamel, K., Melisko, M., & Topp, K. S.（2005）. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical Journal of Oncology Nursing, 9（2）. 189-93. Yoder, L. H.（2006）. An overview of lung cancer symptom, pathophysiology, and treatment. Medsurg Nursing, 15（4）, 231-235. Zimmerman, M.（2001）. Pathobiology of neuropathic pain. European Journal of Pharmacology, 429（1-3）. 23-37. Zelman, Brandenburg, & Gore,（2006）. Sleep impairment in patient with painful diabetic peripheral neuropathy. Clinical Journal of Pain, 22（8）. 681-685. Zelman, D. C., Gore, M., Dukes, E., Tai, K. S., & Brandenburg, N.（2005）. Validation of a Modified Version of the Brief Pain Inventory for Painful Diabetic Peripheral Neuropathy. Journal of Pain and Symptom Management, 29（4）. 401-410. Zigmond, A. S., & Snaith, P. R.（1983）. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavic,. 67（6）. 361-370. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37328 | - |
| dc.description.abstract | 化學治療引發周邊神經病變（Chemotherapy-Induced Peripheral Neuropathy, CIPN）是某特定類化學治療藥物（platinum類、taxanes類、vinca alkaloids類等）產生的副作用之一，其症狀主要是感覺或運動神經傳導問題，可能造成病患化療的不適，也影響其生活品質。本研究之目的為探討肺癌病患接受化學治療引發周邊神經病變症狀、周邊神經病變性疼痛（Peripheral neuropathic pain, PNP）、症狀困擾對病患情緒（焦慮、憂鬱）及睡眠品質的影響。研究設計為描述相關性研究，採用橫斷式研究設計（cross-sectional design），以立意取樣（purposive sampling）使用結構式問卷進行資料收集，包括：「周邊神經病變評估量表」、「神經性疼痛中文版量表」、「症狀嚴重度量表」、「簡易疼痛量表」、「基本資料表」、「醫院焦慮及憂鬱量表」、「醫療成果指標睡眠品質量表」，收案場所於台北某醫學中心之胸腔內科病房及門診化學治療室，於96年10月至97年5月共收案65人，檢力76％。研究結果顯示83％主訴有CIPN相關症狀，其中以視力糢糊發生率最高（55.4％），其次是手有麻麻的感覺（43.1 %）、腳有麻麻的感覺（40 %），症狀嚴重度皆以有一點最多，28％有PNP症狀主訴，以疼痛造成不愉快、整體疼痛強度、深部及表面疼痛並列為最常見前二項疼痛特質，CIPN症狀嚴重度與PNP嚴重度、完成化療週期數、憂鬱皆有顯著正相關（p<0.05），周邊神經病變評估量表的運動及自主神經面向則與睡眠品質有顯著相關，研究結果反映肺癌病患接受化療引發CIPN及PNP重要症狀特性及潛在問題，而以長期追蹤型研究來了解CIPN及PNP整體變化是有必要的，本研究有助於臨床人員對於CIPN及PNP症狀監測及相關問題更深入瞭解，可提供學術及臨床照護上具體參考依據。 | zh_TW |
| dc.description.abstract | Chemotherapy-Induced Peripheral Neuropathy (CIPN) is one of the major side effects from selected chemotherapeutic agents, including platinum, taxanes, vinca alkaloids. Limited studies have explored these problems. The purpose of this study is to examine (1) the patients’ experiences related to CIPN and peripheral neuropathic pain (PNP) and (2) the relationships of CIPN (and PNP) and anxiety, depression, and quality of sleep in lung cancer patients receiving the above mentioned drugs. A cross-sectional study with purposive sampling was used. Data were collected by (1) Brief Peripheral Neuropathy Inventory (BPNI), (2) Neuropathic Pain Scale (NPS), Symptom Severity Scale (SSS), Hospital Anxiety and Depression Scale (HADS), Medical Outcome Study Sleep Scale (MOS-sleep). Data were collected at a medical center in Taipei. A total of 65 lung cancer patients were recruited. The results showed that 83% had CIPN symptoms with blurred vision (55.4%), numbness on hands ( 43.1 %), numbness on feet (40 %) ranked as the top three symptoms. There are 28% of patients had PNP with “unpleasant,”“intense,”“deep pain” and“surface pain,” described by patients. There were significant correlation among BPNI and NPS, the numbers of chemotherapy courses, and depression. The result suggested the potential problems from CIPN and PNP in lung cancer patients with chemotherapy. Longitudinal studies would be necessary to further examine the changes of CIPN and PNS across time in lung cancer patients. These results can help health professionals better understanding patients’ problems related to CIPN and might enhance patients’quality of life. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T15:24:34Z (GMT). No. of bitstreams: 1 ntu-97-R94426012-1.pdf: 1047627 bytes, checksum: d64b622681479b2701857121d0da9941 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 口試委員會審定書 ii
致謝 iii 中文摘要 iv 英文摘要 v 表目錄 viii 圖目錄 viii 第一章 緒論.......................................... 1 第一節 研究動機與重要性............................ 1 第二節 研究目的.................................... 3 第二章 文獻查證...................................... 4 第一節 肺癌及其治療................................ 4 第二節 化學治療引發周邊神經病變................. 7 第三節 周邊神經病變與情緒及睡眠品質之關係............ 12 第三章 研究方法...................................... 15 第一節 研究設計.................................. 15 第二節 研究對象及場所............................ 16 第三節 研究假設.................................. 17 第四節 名詞解釋及操作型定義...................... 18 第五節 研究工具.................................. 20 第六節 資料收集.................................. 25 第七節 資料處理及分析............................ 26 第八節 研究倫理考量.................................. 27 第四章 研究結果...................................... 28 第一節 肺癌病患之基本資料分析....................... 28 第二節 化療引發周邊神經病變及神經病變性疼痛之特質及嚴重度 ..............................................30 第三節 化療期間症狀困擾及其他相關疼痛情形 .........36 第四節 化療期間情緒及睡眠品質得分情形............. 38 第五節 化療引發周邊神經病變與病人特質及化療特性之關係 ..............................................41 第六節 化療引發周邊神經病變、情緒與睡眠品質之相關性 ..............................................45 第七節 化療引發周邊神病變性疼痛與情緒及睡眠品質相關性 ..............................................47 第五章 討論 .....................................51 第一節 化療引發周邊神經病變及神經病變性疼痛之特質及嚴重度 ............................................51 第二節 症狀嚴重度、其他疼痛、情緒與睡眠品質的情形..53 第三節 化療引發周邊神經病變與病人特質及化療特性之關係56 第四節 化療引發周邊神經病變與情緒及睡眠品質之關係....57 第五節 化療引發周邊神經病變性疼痛與情緒及睡眠品質之關係..............................................58 第六章 結論與建議.................................... 59 第一節 結論........................................ 59 第二節 研究限制與建議............................. 60 第三節 護理上應用.................................. 62 參考資料 中文部分........................................... 63 英文部分........................................... 65 附錄..............................................71 附錄一 周邊神經病變評估量表....................... 71 附錄二 神經性疼痛中文版量表....................... 72 附錄三 症狀嚴重度量表............................. 74 附錄四 簡易疼痛量表............................... 75 附錄五 基本資料表................................. 78 附錄六 醫院焦慮及憂鬱量表......................... 79 附錄七 醫療成果指標睡眠品質量表................... 81 表目錄 表一 引發周邊神經病變化療藥物之累積劑量..............10 表二 肺癌病患基本屬性分析 ............................29 表三 周邊神經病變評估量表得分情形................... 31 表四 周邊神經病變評估量表各面向得分情形............. 32 表五 化療引發周邊神經病變性疼痛（PNP）之得分情形.... 34 表六 其他部位疼痛之疼痛強度與疼痛干擾情形........... 37 表七 化療期間情緒及睡眠品質得分情形................. 39 表八 疼痛、疲倦及呼吸困難與情緒及睡眠品質之相關性... 40 表九 以Pearson’s相關檢測BPNI、NPS與病人及化療特性之相關分析 ..............................................42 表十 用藥組合與BPNI整體平均得分之差異分析........... 43 表十一 用藥劑量與BPNI整體平均得分之差異分析........... 44 表十二 化療引發周邊神經病變與情緒及睡眠品質相關性..... 46 表十三 化療引發周邊神經病變性疼痛與情緒及睡眠品質相關. 48 表十四 有無周邊神經病變性疼痛其情緒及睡眠品質之差異比較 ..............................................49 表十五 CIPN及PNP分組焦慮、憂鬱及睡眠品質得分之差異分析 50 表十六 研究對象與相關研究之BPI得分比較................ 54 圖目錄 圖一 研究架構圖..................................... 14 圖二 NPS量表各題得分分佈盒須圖...................... 35 | |
| dc.language.iso | zh-TW | |
| dc.subject | 肺癌 | zh_TW |
| dc.subject | 化學治療 | zh_TW |
| dc.subject | 周邊神經病變 | zh_TW |
| dc.subject | 周邊神經病變性疼痛 | zh_TW |
| dc.subject | 睡眠品質 | zh_TW |
| dc.subject | peripheral neuropathic pain | en |
| dc.subject | chemotherapy | en |
| dc.subject | Lung cancer | en |
| dc.subject | quality of sleep | en |
| dc.subject | peripheral neuropathy | en |
| dc.title | 肺癌病患接受化學治療引發周邊神經病變及其對情緒與睡眠品質的影響 | zh_TW |
| dc.title | Impact of Chemotherapy-induced Peripheral Neuropathy on Mood and Quality of Sleep in Patients with Lung Cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 孫秀卿,楊志新,謝松蒼 | |
| dc.subject.keyword | 肺癌,化學治療,周邊神經病變,周邊神經病變性疼痛,睡眠品質, | zh_TW |
| dc.subject.keyword | Lung cancer,chemotherapy,peripheral neuropathy,peripheral neuropathic pain,quality of sleep, | en |
| dc.relation.page | 81 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-07-22 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 護理學研究所 | zh_TW |
| 顯示於系所單位： | 護理學系所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 1.02 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。